Timothy Shaver, MD
Rheumatology · Wichita, KSNPI 1336145804
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,199 of the $39,393 with a category attached, or 66.5%. 39 manufacturers reported payments, led by Novartis at 33.9% of the total. Reporting peaked in 2019 at $15,576 and has fallen 58.4% since, to $6,481 in 2025. Among rheumatology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,095 payments — averaging $35.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$13K
- Amgen$6K
- AbbVie$4K
- Pfizer$2K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- plus $10K from 33 others
What the payments were for
- Consulting fees$9102%
- Speaking & faculty fees$9,05623%
- Travel & lodging$2,5216%
- Food & beverage$26,19967%
- Education$7072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,393 in reported general payments places this provider in the 95th percentile of 49 rheumatology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 82 | $670,266 |
| Enbrel SureclickEtanercept | 43 | $378,837 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 42 | $334,858 |
| OtezlaApremilast | 60 | $305,087 |
| RinvoqUpadacitinib | 45 | $303,573 |
| Taltz AutoinjectorIxekizumab | 38 | $272,000 |
| Xeljanz XrTofacitinib Citrate | 42 | $234,617 |
| Cosentyx Unoready PenSecukinumab | 23 | $169,450 |
| Cosentyx Sensoready PenSecukinumab | 15 | $145,697 |
| Orencia ClickjectAbatacept | 23 | $140,690 |
| ActemraTocilizumab | 13 | $129,762 |
| Cimzia (2 Pack)Certolizumab Pegol | 20 | $122,474 |
| Enbrel MiniEtanercept | 12 | $88,271 |
| ForteoTeriparatide | 20 | $84,769 |
| SimponiGolimumab | 17 | $80,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $5,702 | $305,08760 claims |
| AbbVieRinvoq | $4,477 | $303,57345 claims |
| Genentech, Inc.Actemra | $111 | $129,76213 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,647 | $122,47420 claims |
| Lilly USA, LLCForteo | $561 | $84,76920 claims |
| Johnson & JohnsonSimponi | $1,898 | $80,62817 claims |
| GSKBenlysta | $1,026 | $62,04413 claims |
| SanofiKevzara | $383 | $47,00711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 49 rheumatology providers in Kansas.
Other rheumatology in Wichita
- Shadi ShahouriWichita$31K
- Melanie RohrWichita$5K
- Rawaa EbrahemWichita$3K
- Praveena GorantlaWichita$3K
- Brannon DonovanWichita$2K
- Preethi KurakulaWichita$402
- Ruth BuschWichita$327
- Steen MortensenWichita$153
- Teresa ReynoldsWichita$134
- Nadia GibsonWichita$112
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.